RTW Investments LLC lowered its position in shares of Incyte Corporation (NASDAQ:INCY) by 51.3% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 191,151 shares of the biopharmaceutical company’s stock after selling 201,085 shares during the period. Incyte Corporation makes up about 4.5% of RTW Investments LLC’s portfolio, making the stock its 8th largest position. RTW Investments LLC’s holdings in Incyte Corporation were worth $18,024,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in INCY. Canada Pension Plan Investment Board raised its stake in Incyte Corporation by 10.8% in the second quarter. Canada Pension Plan Investment Board now owns 1,005,136 shares of the biopharmaceutical company’s stock worth $80,391,000 after buying an additional 97,815 shares during the period. Skandinaviska Enskilda Banken AB publ raised its stake in Incyte Corporation by 11.6% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 93,541 shares of the biopharmaceutical company’s stock worth $7,481,000 after buying an additional 9,700 shares during the period. Globeflex Capital L P raised its stake in Incyte Corporation by 1.0% in the second quarter. Globeflex Capital L P now owns 10,150 shares of the biopharmaceutical company’s stock worth $812,000 after buying an additional 100 shares during the period. Principal Financial Group Inc. raised its stake in Incyte Corporation by 17.9% in the second quarter. Principal Financial Group Inc. now owns 34,495 shares of the biopharmaceutical company’s stock worth $2,759,000 after buying an additional 5,248 shares during the period. Finally, Asymmetry Capital Management L.P. bought a new stake in Incyte Corporation during the second quarter worth about $2,040,000. 92.62% of the stock is owned by institutional investors and hedge funds.
Shares of Incyte Corporation (NASDAQ:INCY) traded down 0.28% on Monday, reaching $121.36. The company’s stock had a trading volume of 210,893 shares. Incyte Corporation has a 1-year low of $60.30 and a 1-year high of $124.87. The stock has a market capitalization of $22.86 billion, a PE ratio of 163.12 and a beta of 0.78. The stock has a 50-day moving average of $114.79 and a 200 day moving average of $96.93.
This article was originally posted by sleekmoney and is the property of of sleekmoney. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The correct version of this article can be viewed at http://sleekmoney.com/rtw-investments-llc-has-18024000-stake-in-incyte-corporation-incy/1658154.html.
Several brokerages recently weighed in on INCY. Vetr upgraded Incyte Corporation from a “buy” rating to a “strong-buy” rating and set a $133.50 price objective for the company in a research report on Monday, January 30th. Goldman Sachs Group, Inc. (The) increased their price objective on Incyte Corporation from $116.00 to $149.00 and gave the stock a “buy” rating in a research report on Friday, January 27th. Credit Suisse Group began coverage on Incyte Corporation in a research report on Monday, January 23rd. They issued an “outperform” rating and a $137.00 price objective for the company. Barclays PLC increased their price objective on Incyte Corporation from $105.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, January 19th. Finally, JMP Securities reiterated an “outperform” rating and issued a $130.00 price objective on shares of Incyte Corporation in a research report on Wednesday, January 18th. Two analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Incyte Corporation has a consensus rating of “Buy” and a consensus price target of $114.47.
In other Incyte Corporation news, EVP Reid M. Huber sold 11,739 shares of the firm’s stock in a transaction on Monday, January 9th. The stock was sold at an average price of $113.55, for a total value of $1,332,963.45. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 13.70% of the stock is owned by company insiders.
Incyte Corporation Company Profile
Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK).
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/rtw-investments-llc-has-18024000-stake-in-incyte-corporation-incy/1658154.html
Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.